DM1-SMe |
Katalog-Nr.GC18254 |
DM1-SMe ist eine unkonjugierte Form des Maytansinoids in IMGN901. DM1-SMe ist etwa 3- bis 10-mal wirksamer als das Ausgangsarzneimittel Maytansine, mit IC50-Werten im Bereich von 0,003 bis 0,01 nM fÜr DM1-SMe in einer Gruppe menschlicher Tumorzelllinien.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 138148-68-2
Sample solution is provided at 25 µL, 10mM.
DM1-SMe is an analog of mertansine with a thiomethane cap attached to the sulfhydryl group. It has in vitro activity against the pediatric preclinical testing program (PPTP) panel of cancer cell lines with IC50 values of 0.002 to >3 nM.
References:
[1]. Wood, A.C., Maris, J.M., Gorlick, R., et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program Pediatr. Blood Cancer 60(11), 1860-1867 (2013).
Average Rating: 5
(Based on Reviews and 35 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *